[
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Dipped More Than Broader Market Today",
    "summary": "Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=8c4d4447ff7e31bbbc69d93ba866ce9374e7633af7b357339a52f6c2fb7b718a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735598724,
      "headline": "Why Eli Lilly (LLY) Dipped More Than Broader Market Today",
      "id": 132208526,
      "image": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=8c4d4447ff7e31bbbc69d93ba866ce9374e7633af7b357339a52f6c2fb7b718a"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Dividend Stock to Buy In 2024?",
    "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 […]",
    "url": "https://finnhub.io/api/news?id=4ed28e649eab86114f49b2e46fa0487ef27be51239164827781f614ec488a643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735598080,
      "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Dividend Stock to Buy In 2024?",
      "id": 132208528,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 […]",
      "url": "https://finnhub.io/api/news?id=4ed28e649eab86114f49b2e46fa0487ef27be51239164827781f614ec488a643"
    }
  },
  {
    "ts": null,
    "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
    "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
    "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735585359,
      "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
      "id": 132207437,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459000811/image_459000811.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
      "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a"
    }
  },
  {
    "ts": null,
    "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
    "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
    "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735554600,
      "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
      "id": 132201376,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
      "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d"
    }
  },
  {
    "ts": null,
    "headline": "My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks",
    "summary": "Learn how the power of dividend growth investing and how commitment and a long-term mindset can help you reach your financial goals in this article. Click for more.",
    "url": "https://finnhub.io/api/news?id=36b35b5a54d061f97391d1ec47bcbdd058d712842641076ec316d1e71e3da642",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735552838,
      "headline": "My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks",
      "id": 132202626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153983350/image_2153983350.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Learn how the power of dividend growth investing and how commitment and a long-term mindset can help you reach your financial goals in this article. Click for more.",
      "url": "https://finnhub.io/api/news?id=36b35b5a54d061f97391d1ec47bcbdd058d712842641076ec316d1e71e3da642"
    }
  },
  {
    "ts": null,
    "headline": "Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?",
    "summary": "Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations.  Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.  A stock split doesn't change the overall market value of a company or anything fundamental -- but through the issuance of more shares to current holders, it lowers the per-share price.",
    "url": "https://finnhub.io/api/news?id=7f6a736b111a6d7d2c17afb51a2904302937e1ccece4af66dbcf98cd048c4812",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735551000,
      "headline": "Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?",
      "id": 132201631,
      "image": "https://g.foolcdn.com/editorial/images/801858/gettyimages-1335027284.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations.  Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.  A stock split doesn't change the overall market value of a company or anything fundamental -- but through the issuance of more shares to current holders, it lowers the per-share price.",
      "url": "https://finnhub.io/api/news?id=7f6a736b111a6d7d2c17afb51a2904302937e1ccece4af66dbcf98cd048c4812"
    }
  },
  {
    "ts": null,
    "headline": "THQ: Healthcare Weakness Presents Opportunity, But Potentially Better Alternatives Exist",
    "summary": "I highlight THQ's weakening performance in the healthcare sector due to recent events, suggesting better bets among healthcare CEF peers. Read more here.",
    "url": "https://finnhub.io/api/news?id=765ef9c1d8577ae00e725b6037280610eab3d915acd02998dba085dcb5a488f5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735548781,
      "headline": "THQ: Healthcare Weakness Presents Opportunity, But Potentially Better Alternatives Exist",
      "id": 132202223,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168190/image_1886168190.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "I highlight THQ's weakening performance in the healthcare sector due to recent events, suggesting better bets among healthcare CEF peers. Read more here.",
      "url": "https://finnhub.io/api/news?id=765ef9c1d8577ae00e725b6037280610eab3d915acd02998dba085dcb5a488f5"
    }
  },
  {
    "ts": null,
    "headline": "Nyxoah: The Future Of OSA",
    "summary": "Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 '25. Read why NYXH stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=84a71249dd0929076d14124a4d02982a364422f6ff29b7ea00c874262d5590ec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735531301,
      "headline": "Nyxoah: The Future Of OSA",
      "id": 132200797,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1222911599/image_1222911599.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 '25. Read why NYXH stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=84a71249dd0929076d14124a4d02982a364422f6ff29b7ea00c874262d5590ec"
    }
  }
]